Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Malgorzata Krajewska, Ph.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Sengupta S, Das S, Crespo AC, Cornel AM, Patel AG, Mahadevan NR, Campisi M, Ali AK, Sharma B, Rowe JH, Huang H, Debruyne DN, Cerda ED, Krajewska M, Dries R, Chen M, Zhang S, Soriano L, Cohen MA, Versteeg R, Jaenisch R, Spranger S, Romee R, Miller BC, Barbie DA, Nierkens S, Dyer MA, Lieberman J, George RE. Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Nat Cancer. 2022 10; 3(10):1228-1246. PMID: 36138189.
    Citations: 1     Translation:Humans
  2. Gao Y, Volegova M, Nasholm N, Das S, Kwiatkowski N, Abraham BJ, Zhang T, Gray NS, Gustafson C, Krajewska M, George RE. Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma. Front Oncol. 2021; 11:773186. PMID: 35198433; PMCID: PMC8859926.
  3. Bayles I, Krajewska M, Pontius WD, Saiakhova A, Morrow JJ, Bartels C, Lu J, Faber ZJ, Fedorov Y, Hong ES, Karnuta JM, Rubin B, Adams DJ, George RE, Scacheri PC. Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma. J Clin Invest. 2019 10 01; 129(10):4377-4392. PMID: 31498151; PMCID: PMC6763270.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  4. Krajewska M, Dries R, Grassetti AV, Dust S, Gao Y, Huang H, Sharma B, Day DS, Kwiatkowski N, Pomaville M, Dodd O, Chipumuro E, Zhang T, Greenleaf AL, Yuan GC, Gray NS, Young RA, Geyer M, Gerber SA, George RE. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat Commun. 2019 04 15; 10(1):1757. PMID: 30988284.
    Citations: 58     Fields:    Translation:HumansCells
  5. Krajewska M, Fehrmann RS, de Vries EG, van Vugt MA. Regulators of homologous recombination repair as novel targets for cancer treatment. Front Genet. 2015; 6:96. PMID: 25852742; PMCID: PMC4367534.
    Citations: 33     
  6. Fehrmann RS, Karjalainen JM, Krajewska M, Westra HJ, Maloney D, Simeonov A, Pers TH, Hirschhorn JN, Jansen RC, Schultes EA, van Haagen HH, de Vries EG, te Meerman GJ, Wijmenga C, van Vugt MA, Franke L. Gene expression analysis identifies global gene dosage sensitivity in cancer. Nat Genet. 2015 Feb; 47(2):115-25. PMID: 25581432.
    Citations: 149     Fields:    Translation:HumansCells
  7. Heijink AM, Krajewska M, van Vugt MA. The DNA damage response during mitosis. Mutat Res. 2013 Oct; 750(1-2):45-55. PMID: 23880065.
    Citations: 45     Fields:    Translation:HumansAnimalsCells
  8. Krajewska M, van Vugt MA. Building a great wall around mitosis: evolutionary conserved roles for the Greatwall/MASTL kinases in securing chromosome stability. Cell Cycle. 2010 Oct 01; 9(19):3842. PMID: 20948280.
    Citations:    Fields:    Translation:HumansAnimals
  9. Kaluzny JJ, Szaflik J, Czechowicz-Janicka K, Kaluzny J, Orzalkiewicz A, Zaleska-Zmijewska A, Krajewska M, Stewart JA, Leech JN, Stewart WC. [Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients]. Klin Oczna. 2004; 106(1-2 Suppl):241-2. PMID: 15510513.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  10. Kaluzny JJ, Szaflik J, Czechowicz-Janicka K, Kaluzny J, Orzalkiewicz A, Zaleska A, Krajewska M, Stewart JA, Leech JN, Stewart WC. Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients. Acta Ophthalmol Scand. 2003 Aug; 81(4):349-54. PMID: 12859261.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Krajewska's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (70)
Co-Authors (11)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.